Browse the corpus

Laboratory evaluation of coagulopathy involves specialized tests to study impaired blood clotting, which can lead to excessive bleeding or thrombosis. This process is fundamental to modern hematology practice and essential for diagnosing several coagulopathies. Many medical specialties are involved with initial treatment, monitoring, perioperative assessment, and management to prevent complications. Evaluation encompasses a range of factors, including assessing clotting factors, platelet function, and fibrinolytic pathways. Primary hemostasis disorders typically result in mucocutaneous bleeding, such as easy bruising, epistaxis, and heavy menstruation. Secondary hemostasis disorders typically cause deep tissue hematomas and intracranial hemorrhages, particularly in severe factor deficiencies such as hemophilia A and B. Prolonged coagulation times do not always correlate with bleeding risk, as observed in cases of lupus anticoagulants. Thrombophilia testing is recommended when therapeutic management is concerned, especially in venous thromboembolism or obstetric complications. This activity describes an overview of screening and coagulation tests, the type of specimens required, sample collection, handling and processing, interfering factors, interpretation of results, quality control, and providing healthcare professionals with the knowledge and tools to collaborate effectively within the healthcare team. Enhancing team collaboration and emphasizing the role of laboratory professionals optimizes patient outcomes. Objectives: Select indicated laboratory tests depending on the coagulation disorder under consideration. Identify factors that affect test results and interpretation and develop strategies to minimize interference. Differentiate coagulation pathways to assess and treat patients with clotting disorders to interpret test results. Implement laboratory testing effectively to treat and monitor patients with coagulopathies effectively. Access free multiple choice questions on this topic.

The laboratory evaluation of coagulopathies is critical in numerous medical specialties, offering invaluable insights into the complex molecular and cellular interactions that regulate hemostasis. Coagulopathies encompass a broad spectrum of disorders characterized by abnormalities in blood coagulation, which can result in either excessive bleeding or abnormal clot formation. These conditions present significant clinical challenges, ranging from asymptomatic patients with abnormal coagulation tests to surgical complications, thromboembolic events, or bleeding disorders, necessitating thorough diagnostic assessment and prompt management.[1][2] Beyond hematologists, several medical specialties, including cardiologists, surgeons, anesthesiologists, gynecologists, critical care physicians, oncologists, and emergency medicine clinicians, encounter coagulopathy routinely in their clinical practice. The recent COVID-19 pandemic has underscored the importance of coagulation knowledge in medical practice. Various routine screenings and specialized laboratory tests are available as diagnostic tools. However, healthcare professionals must carefully choose and interpret these tests to identify underlying coagulation disorders, guide appropriate treatment strategies, and optimize patient outcomes.[3][4][5][6][7]

Three main components contribute to coagulation—the vasculature, the cellular compartment, and the plasma. Following vascular damage, tissue factor, and collagen exposure trigger the coagulation cascade. Platelets are central in the cellular compartment, working alongside monocytes, neutrophils, and potentially abnormal cells such as cancer cells. The plasma contains coagulation factors, natural anticoagulants, and microparticles, contributing to thrombin generation. Hemostasis is traditionally divided into primary and secondary stages.[24] Primary Hemostasis Primary hemostasis involves vasoconstriction, platelet adhesion, activation, secretion, and aggregation to form a temporary plug. Platelets adhere to the subendothelium through the von Willebrand factor (vWF) receptor, platelet glycoprotein GPIb, and collagen receptor GPIa through IIa. Several physiological factors activate platelets, including adenosine diphosphate (ADP) through P2Y1 and P2Y12 receptors, epinephrine, thrombin (through PAR1 and PAR4), and collagen (through GPVI). ADP and epinephrine are relatively weak platelet activators, whereas collagen and thrombin are the most potent. As platelets are activated, they change shape and degranulate crucial factors contributing to the coagulation cascade, such as vWF and fibrinogen from α-granules and serotonin, ADP, and Ca++ from δ-granules. As already mentioned, platelets possess numerous receptors, including glycoproteins GPIb-IX-V and GP IIbIIIa, to name a few. GPIb is involved in platelet adhesion to subendothelium by binding to vWF, whereas GPIIbIIIa is crucial in platelet aggregation by binding fibrinogen and vWF.[25][26] Secondary Hemostasis The platelet plug is stabilized through secondary hemostasis, a complex cascade of sequential activation of proenzymes, converging in thrombin generation, subsequently converting fibrinogen to fibrin. Factor XIII (FXIII) stabilizes the fibrin clot.[27] The coagulation cascade is traditionally divided into the extrinsic, intrinsic, and common pathways. Tissue factor activates FVII in the extrinsic pathway, which in turn activates FX (FXa). The intrinsic pathway involves the activation of FXII, FXI, FIX, and FVIII, ending up with FXa. Ultimately, in the common pathway, FXa combines with FV, platelet phospholipids, and calcium ions to convert prothrombin into thrombin, which cleaves fibrinogen into fibrin.[28]

The platelet plug is stabilized through secondary hemostasis, a complex cascade of sequential activation of proenzymes, converging in thrombin generation, subsequently converting fibrinogen to fibrin. Factor XIII (FXIII) stabilizes the fibrin clot.[27] The coagulation cascade is traditionally divided into the extrinsic, intrinsic, and common pathways. Tissue factor activates FVII in the extrinsic pathway, which in turn activates FX (FXa). The intrinsic pathway involves the activation of FXII, FXI, FIX, and FVIII, ending up with FXa. Ultimately, in the common pathway, FXa combines with FV, platelet phospholipids, and calcium ions to convert prothrombin into thrombin, which cleaves fibrinogen into fibrin.[28] These pathways primarily reflect ex vivo mechanisms observed in laboratory testing but do not fully capture in vivo processes. Emerging understanding favors a cellular model of hemostasis over the traditional cascade paradigm, where all interactions start on cellular membranes of platelets and endothelial cells, in 3 overlapping stages—(1) initiation, initiated by tissue factor on cellular membranes; (2) amplification, involving activation of platelets and cofactors to prepare for extensive thrombin production; and (3) propagation, characterized by significant thrombin generation on the platelet surface. The final step is fibrinolysis, with enzymatic degradation of the fibrin clot to balance the uncontrolled fibrin clot formation and prevent catastrophic thrombosis. Plasminogen activators, such as tissue plasminogen activators, activate plasminogen to plasmin, cleaving fibrin at specific lysine residues and dissolving the clot. Opposing forces guided by various fibrinolysis inhibitors, such as plasminogen activator inhibitors (PAI-1 and PAI-2), α2 antiplasmin (α2-AP), and thrombin activatable fibrinolysis inhibitors counterbalance the excessive lysis to prevent from bleeding, by impeding binding of fibrinolytic enzymes to fibrin.[29][30]

Interprofessional communication is crucial in evaluating coagulopathies, given the expertise required for accurate assessment and management. Hemostasis disorders increasingly intersect with several medical disciplines, and close collaboration with the laboratory is essential for interpreting results, avoiding diagnostic pitfalls, and preventing medical misdiagnosis. Moreover, with our evolving understanding of complex hemostatic mechanisms and the emergence of new laboratory tests, education across all medical specialties is paramount for enhancing diagnostic accuracy and optimizing patient management. An ethical concern arises regarding the allocation of responsibility in such interprofessional cases and situations where clinical guidelines are weak, or consensus is lacking. Clinicians must rely on the best available evidence, expert consensus, and patient factors to guide decision-making, involving interdisciplinary discussions, consultation with hemostasis experts, consideration of patient preferences and values, and shared decision-making with patients and their families. Overall, ethical considerations in patients with hemostasis problems emphasize the importance of patient-centered care, interdisciplinary collaboration, evidence-based practice, and respect for patient autonomy and dignity. By upholding these principles, healthcare professionals can navigate complex ethical dilemmas and optimize outcomes for patients with hemostasis disorders.